Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Preliminary Efficacy and Safety of Fispemifene in the Treatment of Hypogonadism: A 4 Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Daily Oral Doses of 100, 200, and 300 mg Fispemifene and Placebo

NCT00290134 is registered in ClinicalTrials.gov with QuatRx Pharmaceuticals Company as lead sponsor.

NCT NCT00290134
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00290134 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Preliminary Efficacy and Safety of Fispemifene in the Treatment of Hypogonadism: A 4 Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Daily Oral Doses of 100, 200, and 300 mg Fispemifene and Placebo
Lead sponsor
QuatRx Pharmaceuticals Company
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2006
Completion date
October 31, 2007
Enrollment
100
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

hypogonadism